11- A new diagnostic test for malabsorption has been analysed and the results have yielded the following 2x2 contingency table.
Disease Disease
yes no
test(+ve) 0.9 0.1
test(-ve ) 0.2 0.8
Applying this test to a case of chronic diarrhoea from a patient group where the prevalence of malabsorption is known to be 20% (probability = 0.2) what is the probability of a patient having malabsorption if they have a positive test?
1) 0.16
2) 0.24
3) 0.48
4) 0.64
5) 0.8
Answers-4
12- Which of the following is true regarding sensory neural hearing loss?
1) The incidence is twice as high in babies admitted to neonatal intensive care units compared with the normal population.
2) The risk is increased in children who have had rubella.
3) Approximately 1 per 1000 children will have greater than 40db hearing loss.
4) The risk is increased in Noonan's Syndrome.
5) The risk is increased in Down's Syndrome.
Answers-3
13- A study of a new chemotherapy drug for lung cancer is reported in a medical journal. The authors state that with the new agent the 5-year mortality rate was 60%. Without treatment the 5-year mortality rate was 80%.
Which of the following represents the Absolute Risk Reduction using this treatment?
1) 10%
2) 20%
3) 25%
4) 33%
5) 40%
Answers-2
14- In significance testing which of these statements is correct?
1) A Type I error is to reject the alternative hypothesis when it should be accepted.
2) A Type II error is to accept the alternative hypothesis when it should be rejected.
3) The probability associated with a Type I error is the significance level.
4) The significance level is determined at the end of a significance test.
5) The significance level is always set to 5%.
Answers-3
15- There is presently no known effective treatment for a chronic disease. A new treatment is known to be effective in animal models and shows promise in short-term studies in patients. There is some theoretical concerns regarding possible hepato- and bone marrow toxicity although thus far, no toxicity have been observed in studies.
What is the most appropriate next step in the drug's development?
1) A case control study
2) No further studies should be done and drug development should be stopped
3) An open study
4) A randomised double blind placebo controlled study
5) A randomised single blind placebo controlled study
Answers-1
More Questions & Answers:-
Page1 Page2 Page3 Page4 Page5
Disease Disease
yes no
test(+ve) 0.9 0.1
test(-ve ) 0.2 0.8
Applying this test to a case of chronic diarrhoea from a patient group where the prevalence of malabsorption is known to be 20% (probability = 0.2) what is the probability of a patient having malabsorption if they have a positive test?
1) 0.16
2) 0.24
3) 0.48
4) 0.64
5) 0.8
Answers-4
12- Which of the following is true regarding sensory neural hearing loss?
1) The incidence is twice as high in babies admitted to neonatal intensive care units compared with the normal population.
2) The risk is increased in children who have had rubella.
3) Approximately 1 per 1000 children will have greater than 40db hearing loss.
4) The risk is increased in Noonan's Syndrome.
5) The risk is increased in Down's Syndrome.
Answers-3
13- A study of a new chemotherapy drug for lung cancer is reported in a medical journal. The authors state that with the new agent the 5-year mortality rate was 60%. Without treatment the 5-year mortality rate was 80%.
Which of the following represents the Absolute Risk Reduction using this treatment?
1) 10%
2) 20%
3) 25%
4) 33%
5) 40%
Answers-2
14- In significance testing which of these statements is correct?
1) A Type I error is to reject the alternative hypothesis when it should be accepted.
2) A Type II error is to accept the alternative hypothesis when it should be rejected.
3) The probability associated with a Type I error is the significance level.
4) The significance level is determined at the end of a significance test.
5) The significance level is always set to 5%.
Answers-3
15- There is presently no known effective treatment for a chronic disease. A new treatment is known to be effective in animal models and shows promise in short-term studies in patients. There is some theoretical concerns regarding possible hepato- and bone marrow toxicity although thus far, no toxicity have been observed in studies.
What is the most appropriate next step in the drug's development?
1) A case control study
2) No further studies should be done and drug development should be stopped
3) An open study
4) A randomised double blind placebo controlled study
5) A randomised single blind placebo controlled study
Answers-1
More Questions & Answers:-
Page1 Page2 Page3 Page4 Page5
No comments:
Post a Comment